Last reviewed · How we verify
Hylan GF-20 alone
Hylan GF-20 is a viscoelastic gel that lubricates and cushions the joint space to reduce friction and pain in osteoarthritis.
Hylan GF-20 is a viscoelastic gel that lubricates and cushions the joint space to reduce friction and pain in osteoarthritis. Used for Osteoarthritis of the knee.
At a glance
| Generic name | Hylan GF-20 alone |
|---|---|
| Also known as | Synvisc One |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Viscosupplement |
| Target | Hyaluronic acid receptor (CD44) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Hylan GF-20 is a cross-linked hyaluronic acid derivative that mimics the properties of synovial fluid. It provides viscosupplementation by restoring the viscoelastic properties of degraded joint fluid, thereby reducing pain, improving joint mobility, and potentially slowing cartilage degeneration in osteoarthritic joints.
Approved indications
- Osteoarthritis of the knee
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Knee pain exacerbation
Key clinical trials
- Outcomes of Injections in Patients Waiting for Total Knee Replacement (PHASE4)
- Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation (PHASE4)
- A Safety Study of Hylan GF-20 to Treat Shoulder Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hylan GF-20 alone CI brief — competitive landscape report
- Hylan GF-20 alone updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI